Trials / Completed
CompletedNCT03726658
Zelquistinel in the Treatment of Adults With Major Depressive Disorder
A Two-Part, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose (Part A) or Twice Daily Dose (Part B) Study of AGN-241751 in Adult Participants With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 226 (actual)
- Sponsor
- Syndeio Biosciences, Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-241751 | AGN-241751 is supplied in tablet form |
| DRUG | Placebo | Placebo is supplied in tablet form |
Timeline
- Start date
- 2018-11-08
- Primary completion
- 2019-10-23
- Completion
- 2019-10-23
- First posted
- 2018-10-31
- Last updated
- 2026-04-07
- Results posted
- 2023-07-07
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03726658. Inclusion in this directory is not an endorsement.